drugset / Trial / NCT05046327
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.
Timeline
- Start
- 2021-10-14
- Primary completion
- 2024-04-06
- Completion
- 2025-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |